On Demand
The Inflation Reduction Act (IRA) is poised to reshape the pharmaceutical industry, and commercial leaders need to be prepared for the sweeping changes it will bring. Join Dan Snyder from Performance Development Group (PDG) and healthcare policy expert Chuck Collins for an in-depth discussion on the IRA’s key provisions and how it will impact your organization.
In this on-demand webinar, you’ll gain insights into:
Don’t miss out on this critical conversation that will help prepare your teams for the future.
Dan Snyder is a seasoned sales and business leader with a rich background in the pharmaceutical/biotech industry. Currently serving as the Senior VP of Sales for Performance Development Group (PDG), Dan has held leadership roles at Astra USA, Diachii Sankyo, Shire, Nitromed, Clarus Therapeutics, Syneos Health, and Delta Point. Adept at overcoming challenges, Dan is known for his passion for sales, commitment to coaching excellence, building high performing teams, and ability to achieve outstanding results.
Chuck Collins leads a managed markets consultancy focused on addressing healthcare delivery disparities across multiple therapeutic areas. With over 30 years of experience in the pharmaceutical industry, Chuck has been advising pharmaceutical clients on the impacts of the Inflation Reduction Act (IRA) since its introduction. His expertise includes managed markets strategy, predictive modeling, and healthcare policy. He has held senior roles at Engage Managed Markets, Boehringer Ingelheim, and Wyeth Pharmaceuticals, and serves as a Senior Fellow at Medonomics, a health policy think tank.
